Skip to content

Clinical trials

Observational Esophageal Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Esophageal Neoplasms Phase: Observational Country / region: China Clear all

104 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20092
20111
20121
20131
20141
20153
20163
20177
20184
20196
20203
20219
202219
202314
20249
202511
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status35
Completed34
Recruiting24
Not yet recruiting4
Active, not recruiting3
Terminated2
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University7
Sun Yat-sen University7
Chinese Academy of Medical Sciences6
Shanghai Zhongshan Hospital5
Changhai Hospital4
Guangdong Provincial People's Hospital4
Hebei Medical University Fourth Hospital4
National Cancer Institute (NCI)4
Henan Cancer Hospital3
Peking University Cancer Hospital & Institute3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Esophageal Neoplasms104
Stomach Neoplasms13
Lung Neoplasms9
Colorectal Neoplasms6
Pancreatic Neoplasms6
Breast Neoplasms5
Esophageal Squamous Cell Carcinoma5
Liver Neoplasms4
Neoplasms4
Uterine Cervical Neoplasms4

Trials

Showing 1 to 25 of 104. Each trial links to its page on Pharma Observatory.

4 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.